e-learning
resources
Berlin 2008
Monday, 06.10.2008
Interstitial lung disease in systemic and vascular disorders
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Cytomegalovirus antigenemina in idiopathic interstitial pneumonias and collagen vascular disease-related lung diseases treated with immunosuppressive drugs
T. Arai, Y. Inoue, K. Tachibana, J. Otsuka, K. Tsuyuguchi, S. Minamoto, M. Kitaichi, K. Suzuki, S. Hayashi, M. Oakada, M. Sakatani (Sakai City, Osaka, Japan)
Source:
Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Session:
Interstitial lung disease in systemic and vascular disorders
Session type:
Thematic Poster Session
Number:
1884
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Arai, Y. Inoue, K. Tachibana, J. Otsuka, K. Tsuyuguchi, S. Minamoto, M. Kitaichi, K. Suzuki, S. Hayashi, M. Oakada, M. Sakatani (Sakai City, Osaka, Japan). Cytomegalovirus antigenemina in idiopathic interstitial pneumonias and collagen vascular disease-related lung diseases treated with immunosuppressive drugs. Eur Respir J 2008; 32: Suppl. 52, 1884
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Rituximab in the management of idiopathic inflammatory myopathies complicated by interstitial lung disease
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017
Idiopathic nonspecific interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders?
Source: Eur Respir J 2011; 38: 384-391
Year: 2011
Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia
Source: Eur Respir J 2005; 25: 528-533
Year: 2005
Occult connective tissue diseases mimicking idiopathic interstitial pneumonias
Source: Eur Respir J 2008; 31: 11-20
Year: 2008
Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Interstitial lung disease with autoimmune features
Source: Eur Respir Mon 2011; 54: 104-117
Year: 2011
Novel markers of connective tissue disease in patients with idiopathic interstitial pneumonia
Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Year: 2008
Cyclosporine A in the treatment of idiopathic pulmonary fibrosis/usual interstitial pneumonia
Source: Eur Respir J 2002; 20: Suppl. 38, 62s
Year: 2002
Clinical features of usual interstitial pneumonia-correlation between idiopathic pulmonary fibrosis and connective tissue disease associated with usual interstitial pneumonia
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy},
Source: Eur Respir J 2012; 40: 641-648
Year: 2012
Antifibrotic treatment in progressive non-IPF fibrotic interstitial lung diseases
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019
Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
Source: Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019
Year: 2019
Experience with antifibrotics treatment in progressive interstitial lung diseases non-IPF
Source: Virtual Congress 2021 – Clinical evolution, management and outcomes of patients with rare diffuse parenchymal lung diseases
Year: 2021
Significance of connective tissue disease features in idiopathic interstitial pneumonia
Source: Eur Respir J 2012; 39: 661-668
Year: 2012
Fibrotic CTD and interstitial pneumonia with autoimmune features (IPAF): immunosuppressive or/and anti-fibrotic treatment?
Source: Virtual Congress 2020 – Rheumatology: understanding connective tissue disease in patients with interstitial lung disease
Year: 2020
Idiopathic interstitial pneumonia and connective tissue disorder-related interstitial lung disease
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 978-1-904097-51-8, page=170
Year: 2007
Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases
Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019
Year: 2019
The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype
Source: Eur Respir Rev, 27 (150) 180077; 10.1183/16000617.0077-2018
Year: 2018
Clubbing in patients with fibrotic interstitial lung diseases
Source: International Congress 2017 – ILDs: clinical problems
Year: 2017
The efficacy of cyclosporine A in patients with clinicoradiologically diagnosed idiopathic nonspecific interstitial pneumonia
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept